<SEC-DOCUMENT>0001628280-25-039883.txt : 20250812
<SEC-HEADER>0001628280-25-039883.hdr.sgml : 20250812
<ACCEPTANCE-DATETIME>20250812161035
ACCESSION NUMBER:		0001628280-25-039883
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250812
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250812
DATE AS OF CHANGE:		20250812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ZEVRA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001434647
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				205894398
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36913
		FILM NUMBER:		251206786

	BUSINESS ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747
		BUSINESS PHONE:		(321) 939-3416

	MAIL ADDRESS:	
		STREET 1:		1180 CELEBRATION BOULEVARD, SUITE 103
		CITY:			CELEBRATION
		STATE:			FL
		ZIP:			34747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM, INC
		DATE OF NAME CHANGE:	20130530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KEMPHARM INC
		DATE OF NAME CHANGE:	20080507
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zvra-20250812.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:58e395fe-c33c-43a6-ae6c-92d3e9cd0e66,g:4906a67f-a767-4f9c-859c-d409cc83c1a5,d:ac7af6c2a0cb4e5fbbf4bcfaf5aa3326-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>zvra-20250812</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001434647</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="zvra-20250812.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-12</xbrli:startDate><xbrli:endDate>2025-08-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iac7af6c2a0cb4e5fbbf4bcfaf5aa3326_4"></div><div style="min-height:37.44pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August&#160;12, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________________________________________________________</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Zevra Therapeutics, Inc</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter) </span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________________________________________________________</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36913</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">20-5894398</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:-1.19pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1180 Celebration Boulevard, Suite 103</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Celebration</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">FL</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">34747</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">321</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">939-3416</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ZVRA</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-1.88pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Stock Market LLC</span></div><div style="padding-right:-1.88pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Nasdaq Global Select&#160;Market)</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160; &#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; &#160;&#9744;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:35.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iac7af6c2a0cb4e5fbbf4bcfaf5aa3326_138"></div><hr style="page-break-after:always"/><div style="min-height:37.44pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;12, 2025, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the second quarter&#160;ended June&#160;30, 2025, as well as information regarding&#160;a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Tuesday, August&#160;12, 2025, at 4:30&#160;p.m. ET. A copy of the press release is&#160;furnished as Exhibit 99.1&#160;to this Current Report on Form 8-K.&#160;The information contained in the press release,&#160;furnished as Exhibit 99.1 shall not be deemed &#8220;filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of Zevra's&#160;filings under the Securities Act of 1933, as amended, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iac7af6c2a0cb4e5fbbf4bcfaf5aa3326_155"></div><div style="-sec-extract:summary;padding-right:-9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements and Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.907%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.564%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.38pt;text-align:justify"><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="zvra-20250812xex991.htm">Press Release&#160;dated August 12,&#160;2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:35.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:37.44pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.010%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Zevra Therapeutics, Inc.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: August&#160;12, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy J. Sangiovanni</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Timothy J. Sangiovanni, CPA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Finance and Corporate Controller</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:35.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>zvra-20250812xex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie56d24023ae44fd29ca1fcb35bf80073_1"></div><div style="min-height:28.8pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="zevralogo.jpg" src="zevralogo.jpg" style="height:58px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Zevra Reports Second Quarter 2025 Financial Results and Corporate Update</font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million</font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial launches and development programs</font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font><br></font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Submitted a Marketing Authorisation Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C </font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Company to host conference call and webcast TODAY, August&#160;12, 2025, at 4&#58;30 p.m. ET</font></div><div style="padding-left:4pt;padding-right:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CELEBRATION, Fla., August&#160;12, 2025 -- Zevra Therapeutics, Inc. (NasdaqGS&#58; ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the three and six months ended June&#160;30, 2025.</font></div><div style="padding-left:8pt;text-align:justify"><font><br></font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;This is an exciting time of growth for Zevra,&#8221; said Neil F. McFarlane, Zevra&#8217;s President and Chief Executive Officer. &#8220;Following approval late last year, we are focused on executing the U.S. launch of MIPLYFFA&#174;, and we believe the remarkable performance in the second quarter sets a strong foundation for continued momentum. As the only treatment that has been shown to halt disease progression by addressing its underlying pathology, we are invigorated by the meaningful impact MIPLYFFA is bringing to people diagnosed with Niemann-Pick disease type C (NPC). Now, with the recent submission of the Marketing Authorisation Application (MAA) in the E.U., we seek to expand these differentiated benefits to greater numbers of patients with this debilitating disease.&#8221; </font></div><div style="padding-left:8pt;text-align:justify"><font><br></font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commercial Highlights</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">MIPLYFFA&#58; 7 prescription enrollment forms&#160;during Q2 2025, bringing the total since product launch to 129.&#8239;Market access has reached 52% of covered lives, which is in line with expectations at this stage of the launch. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">OLPRUVA&#58; 1 prescription enrollment form during Q2 2025, bringing the total since product launch to 29. Market access has increased to 79% of covered lives. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pipeline and Innovation Highlights</font></div><div style="text-align:justify;text-indent:9pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Recently filed the arimoclomol MAA with the European Medicines Agency (EMA) for the treatment of NPC, meeting the Company&#8217;s guidance for submission in second half of 2025. Arimoclomol has been designated an Orphan Medicinal Product by the EMA. Arimoclomol is currently marketed in the U.S. under the brand name MIPLYFFA&#174;. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Enrolled 7 patients in the Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome during Q2 2025, bringing the total number of enrolled patients to 39. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate Highlights</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">On April 1, 2025, Zevra closed the sale of its Pediatric Rare Disease Priority Review Voucher (&#8220;PRV&#8221;) for gross proceeds of $150.0 million, bolstering the Company&#8217;s balance sheet with non-dilutive capital. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie56d24023ae44fd29ca1fcb35bf80073_68"></div><hr style="page-break-after:always"><div style="min-height:28.8pt;width:100%"><div><font><br></font></div></div><div style="padding-left:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Financial Highlights</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Revenue, Net&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#160;$25.9 million for Q2 2025, which includes $21.5 million of MIPLYFFA net revenue, $0.3 million of OLPRUVA net revenue, $2.6 million in net reimbursements from the French EAP for arimoclomol, $1.2 million in royalties and other reimbursements under the AZSTARYS&#174; license agreement, and an upfront payment of $0.3 million from the out-license of our dextrorphan prodrug. For Q2 2024, total net revenue was $4.4 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cost of Product Revenue&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;$14.0 million for Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025, which includes $1.6 million of non-cash intangible asset amortization for the period, and inventory obsolescence expense of $11.7 million. Based on our quarterly assessment of the recoverability of certain intangible assets and inventory related to OLPRUVA in accordance with U.S. GAAP, the prevailing trend for enrollments, paid authorizations, as well as market and competitive landscape dynamics, we have also recognized a non-cash charge of $58.7 million for impairment of intangible assets as of June&#160;30, 2025. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Operating Expenses&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;$24.2 million for Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025, which includes non-cash stock compensation expense of $2.5 million. For Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024, total operating expenses were $23.1 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">R&#38;D expense was $3.4 million for Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025, which was a decrease of $7.1 million compared to Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024 due primarily to a decrease in third-party costs upon completion of the KP1077 Phase 2 trial, combined with a decrease in personnel-related costs. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">SG&#38;A expense was $20.8 million for Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025, which was an increase of $8.2 million compared to Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024. Period-over-period increase was&#8239;primarily related to an increase in personnel-related costs, professional fees, and other expenses associated with our commercial, medical and launch activities.&#8239;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Other Income&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">$147.9 million for Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2025, which includes $148.3 million of net proceeds from the sale of the PRV which closed on April 1, 2025, and offset by $0.4 million in non-cash fair value adjustment.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Net Income (Loss)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#160;$74.7 million, or $1.24 per basic share and $1.21 per diluted share for Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2025, compared to a net loss of $(19.9) million, or $(0.48) per basic and diluted share, in Q2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2024.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Excluding $148.3 million of net proceeds from the one-time PRV sale, the $58.7 million non-cash impairment charge related to intangible assets, and the $11.7 million inventory obsolescence charge recognized during the quarter, adjusted net loss was $(3.2) million, or $(0.06) adjusted net loss per basic and diluted share for Q2 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Cash Position&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;Cash, cash equivalents and securities were $217.7 million as of June&#160;30, 2025.&#8239;Based on the Company&#8217;s current operating forecast, we believe we have sufficient resources and financial flexibility to execute on our strategic priorities independent from the capital markets. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:12.53pt">Common and Fully Diluted Shares O&#47;S&#58;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, total shares of common stock outstanding were 55,084,204, and fully diluted common shares were 67,962,774, which included 7,395,043 issuable from outstanding awards under equity incentive plans, and 5,483,527&#160;shares issuable upon exercise of warrants.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:198pt"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted net loss and adjusted net loss per share are non-GAAP financial measures. Management believes that adjusted net loss and adjusted net loss per share provide useful information for investors, and management uses these supplemental measures to assess the Company&#8217;s operating performance. Adjusted net loss and adjusted net loss per share have limitations as analytical tools because they do not reflect all of the amounts associated with our results of operations as determined in accordance with U.S. GAAP. Additionally, they may not be comparable to similarly titled measures of other companies, including in our industry, limiting the usefulness of those measures for comparative purposes. Because of these limitations, these non-GAAP financial measures should be considered along with other operating and financial performance measures presented in accordance with U.S. GAAP. The presentation of these non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with U.S. GAAP.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie56d24023ae44fd29ca1fcb35bf80073_85"></div><hr style="page-break-after:always"><div style="min-height:28.8pt;width:100%"><div><font><br></font></div></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call Information</font></div><div style="padding-left:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Zevra will host a conference call and audio webcast TODAY at 4&#58;30 p.m. ET to discuss its corporate update and financial results for the second quarter 2025.&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The audio webcast will be accessible via the Investor Relations section of the Company&#8217;s website,&#160;http&#58;&#47;&#47;investors.zevra.com&#47;. An archive of the audio webcast will be available for ninety (90) days beginning at approximately 5&#58;30 p.m. ET on August&#160;12, 2025.&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, interested participants and investors may access the conference call by dialing either&#58;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">(800) 245-3047&#160;(United States)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">+1 (203) 518-9765&#160;(International)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Conference ID&#58; ZVRAQ225</font></div><div><font><br></font></div><div style="padding-left:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inducement Awards </font></div><div style="padding-left:8pt"><font><br></font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since August&#160;19, 2024, the Company has granted inducement equity awards to 9 individuals totaling 54,875 shares of restricted stock units of Zevra&#8217;s common stock, vesting over three years, with 33 1&#47;3% vesting on the first anniversary of each respective individual&#8217;s start date, and the remainder vesting in two equal annual installments thereafter, and 49,750 options to purchase Zevra&#8217;s common stock, vesting over four years, with 25% vesting on the first anniversary of each respective individual&#8217;s start date, and the remainder vesting in three equal annual installments thereafter. The inducement awards were granted under the Zevra Therapeutics, Inc. 2023 Employment Inducement Award Plan (as amended and&#47;or restated, the Inducement Award Plan) and, in each case, an award agreement thereunder. </font></div><div style="padding-left:8pt;text-align:justify"><font><br></font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The stock option awards were granted as inducement material to the individuals entering into employment with Zevra in accordance with Nasdaq Rule 5635(c)(4). The Inducement Award Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zevra, or following a bona fide period of non-employment, as an inducement material to such individuals&#8217; entering into employment with Zevra. </font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie56d24023ae44fd29ca1fcb35bf80073_107"></div><hr style="page-break-after:always"><div style="min-height:28.8pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About MIPLYFFA&#174;&#160;(arimoclomol)</font></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MIPLYFFA (arimoclomol) is Zevra&#8217;s approved therapy for the treatment of Niemann-Pick disease type C (NPC).&#160;Approved by the U.S. Food and Drug Administration on Sep. 20, 2024, MIPLYFFA (arimoclomol) increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes. MIPLYFFA has also been shown to reduce unesterified cholesterol in the lysosomes of human NPC fibroblasts. The clinical significance of these findings is not fully understood. In the pivotal phase 3 trial, MIPLYFFA halted disease progression compared to placebo over the one-year duration of the trial when measured by the only validated disease progression measurement tool, the NPC Clinical Severity Scale. MIPLYFFA has also received Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC. The extensive data generated for MIPLYFFA has shown long-term, meaningful clinical outcomes with 5 and in some patients 7 years of patient experience across more than 270 NPC patients worldwide through a Phase 2&#47;3 clinical trial, Open-Label Extension (OLE) study, Expanded Access Programs (EAP), and a pediatric sub-study, which is the most expansive clinical development program in NPC to date. Zevra has submitted a Marketing Authorization Application to the European Medicines Agency for the evaluation of arimoclomol for the treatment of Niemann-Pick disease type C.</font></div><div style="padding-left:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INDICATIONS AND USAGE</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.</font></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IMPORTANT SAFETY INFORMATION</font></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Hypersensitivity Reactions&#58;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1&#58; two patients reported both urticaria and angioedema (6%) and one patient (3%) experienced urticaria alone within the first two months of treatment. Discontinue MIPLYFFA in patients who develop severe hypersensitivity reactions. If a mild or moderate hypersensitivity reaction occurs, stop MIPLYFFA and treat promptly. Monitor the patient until signs and symptoms resolve.</font></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Embryofetal Toxicity&#58;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MIPLYFFA may cause embryofetal harm when administered during pregnancy based on findings from animal reproduction studies. Advise pregnant females of the potential risk to the fetus and consider pregnancy planning and prevention for females of reproductive potential.</font></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Increased Creatinine without Affecting Glomerular Function&#58;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Across clinical trials of MIPLYFFA, mean increases in serum creatinine of 10% to 20% compared to baseline were reported. These increases occurred mostly in the first month of MIPLYFFA treatment and were not associated with changes in glomerular function.</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function. Increases in creatinine reversed upon MIPLYFFA discontinuation.</font></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The most common adverse reactions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in Trial 1 (&#8805;15%) in MIPLYFFA-treated patients who also received miglustat were upper respiratory tract infection, diarrhea, and decreased weight.</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three (6%) of the MIPLYFFA-treated patients had the following adverse reactions that led to withdrawal from Trial 1&#58; increased serum creatinine (one patient), and progressive urticaria and angioedema (two patients). Serious adverse reactions reported in MIPLYFFA-treated patients were hypersensitivity reactions including urticaria and angioedema.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1 800-FDA-1088 or www.fda.gov&#47;medwatch.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:28.8pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Drug Interaction(s)&#58;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Arimoclomol is an inhibitor of the organic cationic transporter 2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates. When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use in Females and Males of Reproductive Potential&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Based on animal findings, MIPLYFFA may impair fertility and may increase post-implantation loss and reduce maternal, placental, and fetal weights.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Renal Impairment&#58;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR &#8805;15 mL&#47;minute to &#60;50 mL&#47;minute is lower than the recommended dosage (less frequent dosing) in patients with normal renal function.</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">MIPLYFFA capsules for oral use are available in the following strengths&#58; 47 mg, 62 mg, 93 mg, and 124 mg.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About OLPRUVA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#174;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">OLPRUVA (sodium phenylbutyrate) is Zevra&#8217;s approved treatment for the treatment of certain UCDs.&#160;OLPRUVA (sodium phenylbutyrate) for oral suspension is a prescription medicine used along with certain therapies, including changes in diet, for the long-term management of adults and children weighing 44&#160;pounds (20 kg) or greater and with a body surface area (BSA) of 1.2 m</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or greater, with UCDs, involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). OLPRUVA is not used to treat rapid increase of ammonia in the blood (acute hyperammonemia), which can be life-threatening and requires emergency medical treatment.&#160;For more information, please visit www.OLPRUVA.com.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Important Safety Information</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain medicines may increase the level of ammonia in your blood or cause serious side effects when taken during treatment with OLPRUVA.&#160;Tell your doctor about all the medicines</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> you or your </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">child take, especially if you or your child take corticosteroids, valproic acid, haloperidol, and&#47;or probenecid.</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">OLPRUVA can cause serious side effects, including&#58; 1) nervous system problems (neurotoxicity). Symptoms include sleepiness, tiredness, lightheadedness, vomiting, nausea, headache, confusion, 2) low potassium levels in your blood (hypokalemia) and 3) conditions related to swelling (edema). OLPRUVA contains salt (sodium), which can cause swelling from salt and water retention. Tell your doctor right away if you or your child get any of these symptoms.&#160;Your doctor may do certain blood tests to check for side effects during treatment with OLPRUVA.&#160;If you have certain medical conditions such as heart, liver or kidney problems, are pregnant&#47;planning to get pregnant or breast-feeding, your doctor will decide if OLPRUVA is right for you.</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The most common side effects of OLPRUVA include absent or irregular menstrual periods, decreased appetite, body odor, bad taste or avoiding foods you ate prior to getting sick (taste aversion).&#160;These are not all of the possible side effects of OLPRUVA.&#160;Call your doctor for medical advice about side effects.&#160;You may report side effects to U.S. FDA at 1-800-FDA-1088.</font></div><div style="padding-left:8pt;text-align:justify"><font><br></font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Celiprolol</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Celiprolol is Zevra&#8217;s investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS).&#160;Celiprolol has been granted Orphan Drug and Breakthrough Therapy designations by the U.S. FDA.&#160;Zevra recently restarted enrollment in the DiSCOVER trial, a Phase 3 trial being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. FDA.&#160;Celiprolol&#8217;s mechanism of action is designed to reduce the mechanical stress on collagen fibers within the arterial wall through vascular dilation and smooth muscle relaxation.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie56d24023ae44fd29ca1fcb35bf80073_123"></div><hr style="page-break-after:always"><div style="min-height:28.8pt;width:100%"><div><font><br></font></div></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Zevra Therapeutics, Inc.</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Zevra Therapeutics, Inc. is a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expanded access programs are made available by Zevra Therapeutics, Inc. and its affiliates and are subject to the Company's Expanded Access Program (EAP) policy, as published on its website. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician's discretion.</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information, please visit&#160;www.zevra.com&#160;or follow us on&#160;X&#160;and&#160;LinkedIn.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cautionary Note Concerning Forward-Looking Statements</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.&#160;Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding our growth&#59; the U.S. launch and potential global expansion of MIPLYFFA&#174;&#59; submissions to, review by, and discussions with the EMA regarding arimoclomol&#59; promise and potential impact of our preclinical or clinical trial data&#59; the initiation, timing and results of any clinical trials or readouts, the content, information used for, timing or results of any NDA submissions or resubmissions for any products or product candidates for any specific disease indication or at any dosage&#59; the potential benefits of any of our products or product candidates for any specific disease or at any dosage&#59; future research and development activities&#59; our strategic and product development objectives, including with respect to becoming a leading, commercially focused rare disease company&#59; our financial position, including our cash balance and anticipated cash runway&#59; and the timing of any of the foregoing.&#160;Forward-looking statements are based on information currently available to Zevra and its current plans or expectations.&#160;They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.&#160;These and other important factors are described in detail in the &#8220;Risk Factors&#8221; section of Zevra&#8217;s Annual Report on Form 10-K for the year ended&#160;December&#160;31, 2024, filed on March&#160;12, 2025, Quarterly Report on Form 10-Q for the three and six months ended June&#160;30, 2025 to be filed with the SEC, as well as and Zevra&#8217;s other filings with the&#160;Securities and Exchange Commission.&#160;While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct.&#160;These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zevra Contact</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nichol Ochsner<br>+1 (732) 754-2545<br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">nochsner&#64;zevra.com</font></div><div style="text-align:center"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie56d24023ae44fd29ca1fcb35bf80073_37"></div><hr style="page-break-after:always"><div style="min-height:28.8pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;ZEVRA THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(in thousands, except share and per share amounts)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six months ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,881&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,449&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,282&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue (excluding $1,616 and $1,546 in intangible asset amortization for the three months ended June&#160;30, 2025, and 2024, respectively, and $3,231 and $3,074 in intangible asset amortization for the six months ended June&#160;30, 2025, and 2024, respectively, shown separately below)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,573&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,724&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,748&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,616&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,546&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,231&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,074&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangible assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,710&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,710&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,433&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,521&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,691&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,798&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,782&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,604&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,327&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,535&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,215&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,125&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,018&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,333&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,039)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,795)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,401)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,281)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of PRV</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,325&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,325&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,009)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,110)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,978)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,845)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment related to warrant and CVR liability</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,779&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,406&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustment related to investments</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,199&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,945&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,390&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,734&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,906&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,855)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,989&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,547)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,199)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,381)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,707&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,925)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,608&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,547)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share of common stock&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.24&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.48)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.87)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.48)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.87)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,780,938&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,899,087&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,440,100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,839,582&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,324,903&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,899,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,062,443&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,839,582&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie56d24023ae44fd29ca1fcb35bf80073_51"></div><hr style="page-break-after:always"><div style="min-height:28.8pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;ZEVRA THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(in thousands, except share and par value amounts)</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,712&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,785&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities at fair value, current</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,899&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,711&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts and other receivables</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,266&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,509&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,052&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, current</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,108&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,970&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,337&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,027&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities at fair value, noncurrent</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,089&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,010&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, noncurrent</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,999&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,701&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,701&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,053&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,993&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,277&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,127&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,842&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,456&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of discount and rebate liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,599&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,989&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,866&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,832&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,065&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,692&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,504&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,807&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,804&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payable</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,479&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,431&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount and rebate liabilities, less current portion</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,862&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,655&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,630&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,047&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,461&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:28.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of June&#160;30, 2025, or December&#160;31, 2024</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.0001 par value, 250,000,000 shares authorized&#59; 56,659,896 shares issued and 55,084,204 shares outstanding as of June&#160;30, 2025&#59; 55,246,401 shares issued and 53,670,709 shares outstanding as of December&#160;31, 2024</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,316&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,302&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,983)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,983)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433,681)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(505,289)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,428)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,230&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,666&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,277&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,127&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>zvra-20250812.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:58e395fe-c33c-43a6-ae6c-92d3e9cd0e66,g:4906a67f-a767-4f9c-859c-d409cc83c1a5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zvra="http://www.kempharm.com/20250812" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.kempharm.com/20250812">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zvra-20250812_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zvra-20250812_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.kempharm.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>zvra-20250812_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:58e395fe-c33c-43a6-ae6c-92d3e9cd0e66,g:4906a67f-a767-4f9c-859c-d409cc83c1a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_0886af9b-d377-481d-b6cb-55e1af08091a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_744983b1-f908-41e1-a963-f076d4edd5ca_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_52fa58e3-4e00-4706-a752-b07da9e66782_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ed983863-4182-4cf4-94bb-bdfab60da804_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_c3850c51-a1b1-4055-b955-ca68b134d826_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_005de9c1-00bf-447d-a630-a21f3b534ee3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_551bdbac-4bb5-4e75-9da9-4e9867123735_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_feec8a59-2c86-4acc-a81f-5bd5b52de918_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_011fe6a9-813c-4782-8838-140422a45076_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_208d3406-4927-43cb-9489-28f0fe2458b3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_86e3537f-3cf1-42e1-a472-dd423b346fca_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f19a4cf2-b006-4d79-8814-6da9b357bec8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9d45b24e-5fda-4e94-876c-e37abd900737_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9451c4e4-cd94-486c-87a1-b13997f75832_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_581e81b0-60e8-4fe8-bf3e-bc882fdfcd4b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f84819d6-fefa-4fbc-bad2-e5f4605616b7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_956bcf61-b59b-4d92-bec7-6a272609f603_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4dc11607-29f4-402f-acb6-54ae2c05605e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_11a580cc-67d7-4eab-9b79-87cad88649ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7c5b643d-9663-40d7-b80f-85b37144c165_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a2143ab3-406e-4dc3-856c-bb0ecdb8705f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e07bc075-19ec-46c6-811c-7a27838cf7f8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>zvra-20250812_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:58e395fe-c33c-43a6-ae6c-92d3e9cd0e66,g:4906a67f-a767-4f9c-859c-d409cc83c1a5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.kempharm.com/role/Cover" xlink:type="simple" xlink:href="zvra-20250812.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.kempharm.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b8a78d67-3403-4f6d-9225-5a60358a6a5d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_DocumentType_b8a78d67-3403-4f6d-9225-5a60358a6a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1a831991-03b8-4201-a6c6-8735357c7efd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_DocumentPeriodEndDate_1a831991-03b8-4201-a6c6-8735357c7efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_322d6290-5f14-441c-8aba-a67cc9886056" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityRegistrantName_322d6290-5f14-441c-8aba-a67cc9886056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e22ea918-a4a5-47e4-b751-4313e4ab6379" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e22ea918-a4a5-47e4-b751-4313e4ab6379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_43de68ec-8fbd-4834-8aa3-452752826a16" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityFileNumber_43de68ec-8fbd-4834-8aa3-452752826a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1108013e-37c5-4533-9a6d-4a3150192877" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityTaxIdentificationNumber_1108013e-37c5-4533-9a6d-4a3150192877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_244628db-66ed-4f77-b1b5-d66ec3ce81ff" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityAddressAddressLine1_244628db-66ed-4f77-b1b5-d66ec3ce81ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_50126738-362e-4b2f-9a43-b7dbb891cffc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityAddressCityOrTown_50126738-362e-4b2f-9a43-b7dbb891cffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_288885d8-6dc4-4a06-94de-17f1bffd84a1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityAddressStateOrProvince_288885d8-6dc4-4a06-94de-17f1bffd84a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_46b023a5-06e0-4fed-90e2-12d1ec8a9013" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityAddressPostalZipCode_46b023a5-06e0-4fed-90e2-12d1ec8a9013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_06d031e1-c007-4d38-a3f4-9a7ed04c9115" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_CityAreaCode_06d031e1-c007-4d38-a3f4-9a7ed04c9115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e7ff6178-c47e-4a87-8aa2-835dfca959d4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_LocalPhoneNumber_e7ff6178-c47e-4a87-8aa2-835dfca959d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ab2f81d0-9701-4448-9cfa-252dd20c72c0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_WrittenCommunications_ab2f81d0-9701-4448-9cfa-252dd20c72c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_d76434ff-ad8e-4db2-bb19-e536c0d676c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_SolicitingMaterial_d76434ff-ad8e-4db2-bb19-e536c0d676c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_d6aec425-8017-43c6-a590-ff0007328055" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_PreCommencementTenderOffer_d6aec425-8017-43c6-a590-ff0007328055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d82a6a10-435a-450e-a593-1db01e02804a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d82a6a10-435a-450e-a593-1db01e02804a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_51a292ee-0d53-4c99-a3a5-53ad48d52f86" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_Security12bTitle_51a292ee-0d53-4c99-a3a5-53ad48d52f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1269e51a-bfe3-4519-bc85-2b890a7fc038" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_TradingSymbol_1269e51a-bfe3-4519-bc85-2b890a7fc038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1bc9b08d-d783-41e8-a3de-fa57828ecd27" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_SecurityExchangeName_1bc9b08d-d783-41e8-a3de-fa57828ecd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4031424f-a9f6-4e72-808b-07c98c4cc9e1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityEmergingGrowthCompany_4031424f-a9f6-4e72-808b-07c98c4cc9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1281acc6-eb3c-4b15-b62c-7cfc08dc970a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_AmendmentFlag_1281acc6-eb3c-4b15-b62c-7cfc08dc970a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ec157fa7-1434-4c42-a129-9751b60b633d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6724c3e9-d209-49f4-892c-5d5d6e211eee" xlink:to="loc_dei_EntityCentralIndexKey_ec157fa7-1434-4c42-a129-9751b60b633d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>zevralogo.jpg
<TEXT>
begin 644 zevralogo.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_X0""17AI9@  34T *@    @  8=I  0
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#J
M=-CU+XC^,&%W-(+-6,CC/RPQ9X51TR>GZUMZ9K%I??%S38[9HXM-L%>SM5!P
MO$;+Q]2>/7BI?@O=VUGH>O3O%)++&4>1(ERYCP>@[X^:LJ>#X;Q?O8KO59#U
M$48(Q^+*/YUZTG>4H6=DK*WF4.\#)/I'Q;ELYP5:22>)\_Q#!<'Z'"FI].F:
M%[ZXLD$MUH%Q+#+!_P _%BSME??:<_@1Z"NAT'Q5X3UK7]+'D7<>I6X$5M<W
M0&Z3Y=H#,&.2<GKW^M<%I.KMX?\ B1=3W/\ J6NY8+D$<%&<@Y^G!_"DN:;=
MU9V7SW ],^'<]U!>S6<=Q)>Z%/#]JT^X<[BBA@&B)]1N''M[U+\6O#.N^*=!
MM;3PUJ@TVZCN1*\IFDBW)M8;<H">I!Q[52\%:7<>'?'FJZ7%(_\ 9,]N;RW3
M.5'SJ./<9(]QCVKT2N*K+EJ<T1,^<?\ A3WQ)_Z'*/\ \&%S_P#$UQ_Q&\/^
M,? 5K:RZMXQDFENG*QP6]_.7( Y;D 8' _&OK+6=3M-&TJZU'495AM+:,R2.
M>P'\SV [FOA_Q[XGOO'7B^?494D)F<0VMNOS&./.$0#N>>?4DUU8:<ZLKNUE
MY$G8? Z]\3Z]\1M,0:IJ=S:6S&XNA+=2,@C [@G!R2 ![U]>5P7P;\#1^!_"
MD<,RJ=5N\37D@YPV.$!]%SCZY/>N]KEQ-15)^[L,^#M-\0>);_4+6SB\0:HL
MEQ*L*EKR7 +$ 9YZ<U['_P *>^)/_0Y1_P#@PN?_ (FO#_"7_(U:-_U^P_\
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M/$__ $-T?YR_XU[QX2TR;1?#.EZ;=3BXGM+=(7E&?G(&">>:TO/A_P">L?\
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M,;B"%KWQ7$DBHJ"-9)76-0,!0>. ., 8KE_B1\(-<\,>&Y=:OM8CU**W95=
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7\>RU0;& R".."/6BNBHX1?O1O^ C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 12,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">Zevra Therapeutics, Inc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5894398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1180 Celebration Boulevard, Suite 103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Celebration<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">939-3416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZVRA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001434647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="zvra-20250812.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.kempharm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="zvra-20250812.htm">zvra-20250812.htm</File>
    <File>zvra-20250812.xsd</File>
    <File>zvra-20250812_lab.xml</File>
    <File>zvra-20250812_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "zvra-20250812.htm": {
   "nsprefix": "zvra",
   "nsuri": "http://www.kempharm.com/20250812",
   "dts": {
    "inline": {
     "local": [
      "zvra-20250812.htm"
     ]
    },
    "schema": {
     "local": [
      "zvra-20250812.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "zvra-20250812_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zvra-20250812_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://www.kempharm.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zvra-20250812.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "zvra-20250812.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.kempharm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-25-039883-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-039883-xbrl.zip
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MAF*R\M1=%+3Q;U4)\)N8>%4I]!>-NO8X/JZJOQ@F_\Q8Y_]02P,$%     @
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MY8KZV[7_?K:!SK!?Z\7@#U!+ P04    " !0@0Q;@E,FC@0*  !O5   %0
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MCU9ZMC\NOK'>"P[W@\ Q1-DQ$7)9;QI?_J=8=VFSU!GE C-FJH'BT(?CGZ/
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M3 EG=R,1\(F(04P.#7;AV55V=,E#A__[]UL")/OGUYO>,3NBQPVF3[I&F&.
M>(Z& ]KQH< +A$T#T+)"H$- ,("&WTM'LPCXH 3R@E1C(GS@,LR5]WCO048C
M%O! ,$?1"P,PTN%3$!I0A(2AD&<,4IDQT#)C2G]&@1"$K*'\SL:P6Z.0"<^!
M%_\K]H3:@WI-[4'U!<"Z!OLH!'K\_%/'LFHG=R,9,HF<%ABR+8E!1*"U(-D>
M!OX#0 &W5(&<WC%/0 R0#F@UTF4?J^RS_9$'P.<!0O04/F2V3T)V#3"1#K(
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M#,.8:A_0P<M_E#_PP$F"]Y FP8'&U$J/8DXF+O>TT-0T&IVZT;3::GUZ"NG
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M@/1/*E]5J7)X%1@P70=I >A_8(^0$R?2R>)Y8O2^TI5@9AZL$#2BHV[MF#E
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MG\Q/#@\/Z?6YUWF4D0;*S1U-0;.2W(,-PJRF0)01'*\\X>?]1FI)Z#S*=8W
M2VD=4!:C *@N_G_U@\RQ^,LGZ7T3SL430"QS)]84DDYY3(I2,&67?H1$Q;-%
M0%8O@":6=ZU\\OUO^#=5Z:>BQ85<W]X!9)GA2JHF860+II-#E0F4R1?)(0'%
MU4 )4Z#D=21=KR\Q%ET'6+92L-NL\^TGF>C([$;@807>0=*4V>TV,S?PLF^E
M9C/7S5^F./:T2YU++G7?Q0K"P#1@89$?J-J!0=HI%VMFSL1@)/GO6:NV_!>
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MG,=,[$+^W[[O3.''*!J[O_XO4$L! A0#%     @ 4($,6VA#Z%O&#P  =6\
M !$              ( !     'IV<F$M,C R-3 X,3(N:'1M4$L! A0#%
M  @ 4($,6P;:,$QA @  ^08  !$              ( !]0\  'IV<F$M,C R
M-3 X,3(N>'-D4$L! A0#%     @ 4($,6X)3)HX$"@  ;U0  !4
M     ( !A1(  'IV<F$M,C R-3 X,3)?;&%B+GAM;%!+ 0(4 Q0    ( %"!
M#%N*YW:=L08  -XP   5              "  ;P<  !Z=G)A+3(P,C4P.#$R
M7W!R92YX;6Q02P$"% ,4    " !0@0Q;!OXH<5PU  !F7 ( %P
M    @ &@(P  >G9R82TR,#(U,#@Q,GAE>#DY,2YH=&U02P4&      4 !0!)
) 0  ,5D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>zvra-20250812_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zvra-20250812.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434647</identifier>
        </entity>
        <period>
            <startDate>2025-08-12</startDate>
            <endDate>2025-08-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001434647</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-08-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Zevra Therapeutics, Inc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36913</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">20-5894398</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1180 Celebration Boulevard, Suite 103</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Celebration</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">34747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">321</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">939-3416</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ZVRA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
